Literature DB >> 19558250

Effects of antiepileptic drug substitutions on epileptic events requiring acute care.

Karen L Rascati1, Kristin M Richards, Michael T Johnsrud, Teresa A Mann.   

Abstract

STUDY
OBJECTIVES: To determine the odds of antiepileptic drug substitution among patients who had an epileptic event requiring acute care-ambulance service, emergency department visit, or hospitalization-relative to patients who did not have an event, and to compare these results with those from a recent study involving a similar method but different patients.
DESIGN: Case-control analysis. DATA SOURCE: United States health care claims from the PharMetrics database. PATIENTS: A cohort of patients aged 12-64 years with a primary diagnosis of epilepsy between October 1, 2005, and December 31, 2006; 991 cases (patients who experienced an epileptic event requiring acute care) and 2973 controls (patients who did not have an event) were matched in a 1:3 ratio for sex, age, and type of epilepsy.
MEASUREMENTS AND MAIN RESULTS: Using discordant pairs analysis, we calculated the odds ratio of an epileptic event that required acute care occurring in patients whose antiepileptic drug underwent substitution to an A-rated (therapeutically equivalent) alternative (switch from branded product to generic, generic to branded, or generic to generic) versus those whose drugs were not substituted. For matched data, 109 (11.0%) of 991 cases had an A-rated antiepileptic drug substitution in the 6 months before the event, whereas only 186 (6.3%) of 2973 controls had a substitution (odds ratio 1.84, 95% confidence interval 1.44-2.36). Our results were similar to those of a previous study involving a different patient database, which showed substitution rates of 11.3% for cases versus 6.5% for controls (odds ratio 1.81, 95% confidence interval 1.25-2.63). Our sensitivity analyses were robust, and we found a temporal relationship in that numerous substitutions occurred in the month before the acute event.
CONCLUSION: Patients who had an epileptic event requiring acute care were about 80% more likely than matched controls without an acute event to have recently had an antiepileptic drug substitution. Our replication of a previously published case-control analysis revealed a similar association between substitution involving A-rated antiepileptic drugs and subsequent epileptic events requiring acute care, thereby lending credibility to the findings.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19558250     DOI: 10.1592/phco.29.7.769

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  10 in total

1.  Switching of antiepileptic drug formulations.

Authors:  J Nile Barnes; Karen L Rascati
Journal:  J Pediatr Pharmacol Ther       Date:  2010-04

Review 2.  Switching from brand-name to generic psychotropic medications: a literature review.

Authors:  Julie Eve Desmarais; Linda Beauclair; Howard C Margolese
Journal:  CNS Neurosci Ther       Date:  2010-11-30       Impact factor: 5.243

3.  Generic substitution of lamotrigine among medicaid patients with diverse indications: a cohort-crossover study.

Authors:  Daniel M Hartung; Luke Middleton; Leanne Svoboda; Jessina C McGregor
Journal:  CNS Drugs       Date:  2012-08-01       Impact factor: 5.749

Review 4.  Rational use of generic psychotropic drugs.

Authors:  Maren Carbon; Christoph U Correll
Journal:  CNS Drugs       Date:  2013-05       Impact factor: 5.749

5.  Refilling and switching of antiepileptic drugs and seizure-related events.

Authors:  J J Gagne; J Avorn; W H Shrank; S Schneeweiss
Journal:  Clin Pharmacol Ther       Date:  2010-07-14       Impact factor: 6.875

6.  Seizure risk in brain tumor patients with conversion to generic levetiracetam.

Authors:  Terri S Armstrong; Shauna Choi; Julie Walker; Mark R Gilbert
Journal:  J Neurooncol       Date:  2009-11-21       Impact factor: 4.130

7.  Factors associated with seizure recurrence in epilepsy patients treated with antiepileptic monotherapy: A retrospective observational cohort study using US administrative insurance claims.

Authors:  Natalia Shcherbakova; Karen Rascati; Carolyn Brown; Kenneth Lawson; Suzanne Novak; Kristin M Richards; Linda Yoder
Journal:  CNS Drugs       Date:  2014-11       Impact factor: 5.749

Review 8.  Seizure outcomes following the use of generic versus brand-name antiepileptic drugs: a systematic review and meta-analysis.

Authors:  Aaron S Kesselheim; Margaret R Stedman; Ellen J Bubrick; Joshua J Gagne; Alexander S Misono; Joy L Lee; M Alan Brookhart; Jerry Avorn; William H Shrank
Journal:  Drugs       Date:  2010-03-26       Impact factor: 9.546

9.  Antiepileptic Drug Management in Hospitalized Epilepsy Patients With Nil Per Os Diets: A Retrospective Review.

Authors:  Anna M Bank; Jong Woo Lee; Alexa N Ehlert; Aaron L Berkowitz
Journal:  Neurohospitalist       Date:  2018-09-27

10.  Safety of switching from brand-name to generic levetiracetam in patients with epilepsy.

Authors:  Magdalena Bosak; Agnieszka Słowik; Wojciech Turaj
Journal:  Drug Des Devel Ther       Date:  2017-08-03       Impact factor: 4.162

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.